By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Samus Therapeutics 

Boston  Massachusetts    U.S.A.
Phone: n/a Fax: n/a


Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, including cancer and neurological diseases, such as Alzheimer's, Parkinson's and chronic traumatic encephalopathy. Samus was founded by Drs. Gabriela Chiosis and Larry Norton on research conducted at the Chiosis Laboratory at the Memorial Sloan Kettering Cancer Center, and at Rockefeller University and Weill Cornell Medicine, and is led by Jonathan Lewis, MD, PhD, its Chief Executive Officer. The Company's lead oncology program, epichaperome inhibitor PU-H71, is advancing into Phase 1b or 1b/2 clinical studies in pancreatic cancer, breast cancer, myeloproliferative neoplasms and lymphoma/leukemia. The Company's lead CNS therapeutic, PU-AD, is being studied in Alzheimer's and CTE disease models. In parallel with its therapeutics program, Samus is advancing companion diagnostics PU-PET and PU-CYT.


Founders: Gabriela Chiosis and Larry Norton

CEO: Jonathan Lewis

CMO: James Armitage

CFO: Dick Bagley

CRO: Bob Morgan

CSO: Barbara Wallner

Key Statistics

Ownership: Private

Web Site: Samus Therapeutics

Company News